✕
For Patients & Families
Our Science
About Us
Connect with Us
June 2025: European Academy of Allergy and Clinical Immunology Annual Congress
Long-term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema (HAE): Initial Combined Results from ALPHA-STAR and ALPHA-SOLAR
June 2025: European Academy of Allergy and Clinical Immunology Annual Congress
Unveiling the Underlying Mechanism of Differentiation for STAR-0310, an Anti-OX40 Antibody for Atopic Dermatitis
June 2025: European Academy of Allergy and Clinical Immunology Annual Congress
Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)
June 2025: European Academy of Allergy and Clinical Immunology Annual Congress
ALPHA-ORBIT: a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema (HAE)
May 2025: Eastern Allergy Conference
Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial
March 2025: American Academy of Allergy, Asthma, and Immunology and World Allergy Organization Joint Congress
Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial
March 2025: American Academy of Allergy, Asthma, and Immunology and World Allergy Organization Joint Congress
ALPHA-ORBIT – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Adolescent and Adult Participants with Type 1 and Type 2 Hereditary Angioedema (HAE)
February 2025: Western Society of Allergy, Asthma & Immunology Annual Scientific Session
Navenibart (STAR-0215) Induces Rapid Improvements of Quality of Life in HAE Patients in the ALPHA-STAR Trial
November 2024: Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
Quality of Life (QoL) Improvements in Patients With Hereditary Angioedema (HAE); Interim Results From the Phase 1b/2 ALPHA-STAR Clinical Trial
October 2024: American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Navenibart (STAR-0215) Induces Rapid Improvements of Quality of Life in HAE Patients in the ALPHA-STAR Trial
